- TRIM21 is one of the most unique and functionally specialised members of the TRIM (Tripartite Motif) family of RING finger ubiquitin ligases. Unlike most TRIM proteins, which recognise protein or nucleic‑acid motifs, TRIM21 binds antibodies inside the cytosol. This remarkable ability allows TRIM21 to detect antibody‑coated viruses that have entered the cell and rapidly target them for destruction. As a result, TRIM21 acts as a powerful intracellular immune sensor, bridging humoral immunity with cytosolic antiviral defence.
- Structurally, TRIM21 contains the canonical tripartite motif: an N‑terminal RING finger domain, two B‑box domains, and a coiled‑coil region that mediates dimerisation. These domains form the catalytic and structural core of the protein. The C‑terminal PRY/SPRY domain is responsible for binding the Fc region of IgG, IgA and IgM antibodies with exceptionally high affinity—one of the strongest known non‑covalent interactions in biology. This antibody‑binding capability sets TRIM21 apart from other ubiquitin ligases and underlies its specialised antiviral function.
- When an antibody‑coated virus enters the cytosol, TRIM21 binds the antibody’s Fc region and initiates a rapid ubiquitin‑mediated degradation pathway. Through its RING domain, TRIM21 catalyses the formation of K63‑linked and K48‑linked ubiquitin chains, recruiting the proteasome and triggering the destruction of the viral particle. This process, known as antibody‑dependent intracellular neutralisation (ADIN), eliminates pathogens before they can replicate. TRIM21 also activates immune signalling pathways, including NF‑κB, AP‑1 and IRF transcription factors, amplifying antiviral cytokine production.
- Beyond viral neutralisation, TRIM21 plays roles in autoimmunity, inflammation and protein quality control. It regulates the stability of transcription factors, signalling adaptors and misfolded proteins, linking ubiquitination to broader cellular homeostasis. TRIM21 has been implicated in autoimmune diseases such as systemic lupus erythematosus and Sjögren’s syndrome, where autoantibodies may trigger aberrant TRIM21‑mediated signalling.
- TRIM21 is also a powerful tool in biotechnology. The Trim‑Away technique uses TRIM21 to rapidly degrade specific proteins inside cells by delivering antibodies against the target protein. This method enables fast, antibody‑driven protein depletion without genetic modification, making TRIM21 a valuable tool in cell biology and functional genomics.
- In summary, TRIM21 is a unique intracellular antibody receptor and RING finger ubiquitin ligase that provides a direct link between antibody recognition and cytosolic antiviral defence. Its ability to neutralise pathogens, activate immune signalling and regulate protein stability makes it a central player in innate immunity and a promising target for therapeutic and biotechnological applications.
